Melanoma & Skin Cancer | Specialty

The melanoma & skin cancer condition center is a comprehensive resource for clinical news and expert insights on melanoma & skin cancer. Read more at OncLive.

Treatment Gaps Persist in Advanced Melanoma as Trials Explore Options Beyond Standard Checkpoint and BRAF/MEK Inhibitors

May 27th 2025

Vincent Ma, MD, emphasizes the need for novel therapies for patients with melanoma who are refractory to or ineligible for standard checkpoint inhibition.

Improved Public Awareness and Immunotherapy Drive Down Melanoma Mortality Amid Rising Incidences

May 21st 2025

Vincent Ma, MD, discusses progress in the management of advanced-stage melanoma and the need for primary prevention during Skin Cancer Awareness Month.

Key Areas of Future Research in Advanced Melanoma

May 14th 2025

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss ongoing research to watch in advanced melanoma.

Where RP1 Plus Nivolumab Could Fit in the Treatment Paradigm for Advanced Melanoma Post–PD-1 Inhibition

May 14th 2025

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss where RP1 plus nivolumab could fit in the advanced melanoma treatment paradigm.

Data for RP1 Plus Nivolumab in Metastatic Melanoma After Prior PD-1 Inhibition

May 14th 2025

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, break down data from the IGNYTE trial of RP1 plus nivolumab in advanced melanoma after PD-1 inhibition.

The Promise of Oncolytic Viruses in Advanced Melanoma

May 14th 2025

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, dive into research behind oncolytic viruses in advanced melanoma.

The Role of Interventional Radiologists in Advanced Melanoma Management

May 14th 2025

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss the role of interventional radiologists in melanoma management.

Treatment Challenges After Immunotherapy in Advanced Melanoma

May 14th 2025

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss unmet needs in advanced melanoma after checkpoint inhibition.

The OncFive: Top Oncology Articles for the Week of 4/27

May 3rd 2025

The FDA issues a CRL to a glioma imaging agent, an sBLA seeking approval of an epcoritamab triplet in follicular lymphoma is planned for submission, and more.

China’s NMPA Approves Toripalimab in First-Line Melanoma

April 25th 2025

China’s NMPA has approved the sNDA for toripalimab as a first-line treatment for patients with unresectable or metastatic melanoma.

Immunotherapy Treatment Options in High-Risk or Locally Advanced/Metastatic Non-melanoma and Melanoma: An Evolving Treatment Landscape

April 17th 2025

On April 4, 2025, a select group of international experts in dermatologic oncology participated in a live workshop to discuss treatment options in high-risk or locally advanced/metastatic melanoma and non-melanoma skin cancers in an evolving treatment landscape. Caroline Robert, MD, PhD, led the discussion, obtaining perspectives on the available evidence about immunotherapy options and insights into treatment preferences for high-risk cutaneous squamous cell carcinoma that is either locally advanced (laCSCC) or metastatic (mCSCC) and advanced/metastatic cutaneous melanoma.

Neoadjuvant Darovasertib Receives FDA Breakthrough Therapy Designation for Uveal Melanoma

April 3rd 2025

Updated interim phase 2 data showed the clinical efficacy and safety of neoadjuvant darovasertib monotherapy in localized uveal melanoma.

Silmitasertib Drives Disease Control in Advanced Basal Cell Carcinoma

April 2nd 2025

Silmitasertib generated disease control in patients with locally advanced or metastatic basal cell carcinoma.

Neoadjuvant Pembrolizumab Is Safe and Effective in Resectable Stage III/IV Melanoma

March 30th 2025

Single-dose neoadjuvant pembrolizumab was safe with no surgical delays and boosted MPR rates in resectable melanoma.

New Drug Therapy Combination Shows Promise For Advanced Melanoma Patients

March 28th 2025

A federally funded research team is testing a new combination drug therapy that could both treat and prevent melanoma metastasis to the brain.

Moffitt Study Finds New Immunotherapy Strategy for Enhancing Melanoma Treatment

March 24th 2025

Moffitt Cancer Center researchers found a way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure.

D-MNA Displays Potential as Noninvasive Therapy in Basal Cell Carcinoma of the Skin

March 14th 2025

Micro-array needles containing doxorubicin displayed safety and early activity in basal cell carcinoma of the skin.

MT-8421 Displays Acceptable Safety Profile in First-in-Human Trial for Advanced Solid Tumors

March 11th 2025

MT-8421, a novel engineered toxin body targeting CTLA-4, was not associated with grade 4 or 5 toxicities in patients with select advanced solid tumors.

Five Under 5: Top Oncology Videos for the Week of 2/23

March 2nd 2025

The top 5 videos of the week cover insights in ovarian cancer, NSCLC, CSCC, follicular lymphoma, and CLL.

Immunotherapy Combinations Reign Supreme in Upfront Melanoma Management

February 28th 2025

Teresa Petrella, MD, MHSc, FRCPC, discusses long-term data that inform the sequencing of immunotherapy and targeted therapies for frontline melanoma.